theMednetRegister
  • Community
    • Overview
    • Experts
    • Editors
    • Fellows
    • Code of conduct
    • AI Guidelines for Physicians
  • Company
    • About Us
    • FAQs
    • Privacy Policy
    • Terms of Use
    • Careers
    • Programs
  • News
    • News Releases
    • Press Coverage
    • Publications
    • Blog
  • Contact Us
  • Sign in

Gastroenterology

Adult Congenital Heart Disease   

Questions discussed in this category


Would you consider sotalol to be a suitable non-selective beta blocker for primary prevention of variceal bleeding in a patient who requires sotalol for treatment of arrhythmia in the setting of Fontan-associated liver disease and clinically significant portal hypertension?
1 Answer available
22250


Papers discussed in this category


Lancet (London, England), 2019 Mar 22
β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial.

Related Topics in Gastroenterology

  • Radiation Oncology
  • Gynecologic Oncology
  • Palliation
  • Gastrointestinal Cancers
  • Genitourinary Cancers
  • Melanoma/Skin Cancer
  • Pediatric Hematology/Oncology
  • Thoracic Malignancies
  • Esophageal Cancer
  • Medical Oncology

Copyright © 2025 theMednet
All Rights Reserved.